ScreenerHero

SYRE Spyre Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · spyre.com
80.85USD+0.92%Mkt Cap: 7.02B $P/E: —

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humani…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap7.02B USD
Enterprise Value6.06B USD
Revenue (TTM)—
Gross Profit-215.80M USD
Net Income (TTM)-155.20M USD
Revenue/Share—
Last Price80.85 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees125
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-22.76
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B7.39
EPS (TTM)-1.66
EPS (Forward)-3.52
52W Range
15.4969% of range110.18
52W High110.18 USD
52W Low15.49 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-21.70%
ROA-19.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-169.25M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.27%
Net Debt-1.15B USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio18.53
Quick Ratio18.23
Book Value/Sh10.84 USD
Cash/Share12.99 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateSep 8, 2023
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)120.21 USD
Upside (mean)+48.7%
Target Range97.00 USD – 130.00 USD
97.00+48.7% to mean130.00
# Analysts14
Ownership
Shares Out.86.84M
Float77.70M
Insiders1.66%
Institutions111.62%
Short Interest
Short Ratio10.4d
Short % Float14.71%
Short % Out.13.76%
Shares Short12.13M
Short (prev mo.)11.76M
Technical
SMA 5095.79 (-15.6%)
SMA 20067.92 (+19.0%)
Beta3.11
S&P 52W Chg16.45%
Avg Vol (30d)1.39M
Avg Vol (10d)1.22M
Technical Indicators
RSI (14)36.5
MACD-2.5752
MACD Signal-2.2702
MACD Hist.-0.3050
BB Upper95.49 USD
BB Middle88.36 USD
BB Lower81.24 USD
BB Width16.12%
ATR (14)5.503 USD
Vol Ratio (20d)1.95x